打谷工具
发表于 2025-3-23 13:32:06
Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatmencations for stimulant use disorders. One contributing factor may involve heterogeneity. At the neurobiological level, dual dopamine dysfunction may be undermining medication efficacy, suggesting a need for combination pharmacotherapies. At the population level, individual variability is expressed in
辩论
发表于 2025-3-23 17:18:48
Molecular Mechanism and Cannabinoid Pharmacology,ation of its major cannabinoid constituents, Δ.-tetrahydrocannabinol (THC) and cannabidiol (CBD), led to the synthesis of new cannabinoids (termed synthetic cannabinoids) to understand the mechanisms underlying the pharmacology of .. These pharmacological tools were instrumental in the ultimate disc
边缘带来墨水
发表于 2025-3-23 18:02:56
Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents,ittle or uncertain value. A diverse range of medicines have been tested, representing a broad range of pharmacological strategies. These include tetrahydrocannabinol preparations, various types of antidepressant, anxiolytics, a glutamatergic modulator and the neuropeptide oxytocin. Cannabinoid agoni
Humble
发表于 2025-3-24 01:51:11
Molecular Mechanisms Associated with Nicotine Pharmacology and Dependence, also been garnering increased popularity in its vaporized form, as derived from e-cigarette devices. Thus, an understanding of the molecular mechanisms underlying nicotine pharmacology and dependence is required to ascertain novel approaches to treat drug dependence. In this chapter, we review the
Pathogen
发表于 2025-3-24 04:09:46
http://reply.papertrans.cn/89/8814/881398/881398_15.png
学术讨论会
发表于 2025-3-24 06:36:12
http://reply.papertrans.cn/89/8814/881398/881398_16.png
Diluge
发表于 2025-3-24 12:23:31
http://reply.papertrans.cn/89/8814/881398/881398_17.png
不出名
发表于 2025-3-24 18:22:03
http://reply.papertrans.cn/89/8814/881398/881398_18.png
肥料
发表于 2025-3-24 21:11:24
http://reply.papertrans.cn/89/8814/881398/881398_19.png
低能儿
发表于 2025-3-24 23:52:16
Molecular Mechanisms of Amphetamines, PKC, CaMKII, and OCT3. As is generally true for the development of therapeutics for substance use disorder, there are multiple preclinically promising specific compounds against (meth)amphetamine, for which further development and clinical trials are badly needed.